Abby Hardy, Author at BioTuesdays

Developments

Ziopharm doses first patient in Phase 1/2 pediatric brain tumor trial

Ziopharm Oncology (NASDAQ:ZIOP) dosed the first patient in its Phase 1/2 trial evaluating controlled IL-12 for the treatment of diffuse intrinsic pontine glioma (DIPG). Ziopharm’s controlled IL-12 is a gene therapy...

July 8, 2020

Executive Moves

Strongbridge Biopharma names John Johnson as CEO

John Johnson Strongbridge Biopharma (NASDAQ:SBBP) appointed its executive chairman, John Johnson, as the company’s CEO, effective immediately. Mr. Johnson served as Strongbridge’s chairman since March 2015. In...

July 7, 2020

Developments

Outlook Therapeutics completes enrollment in pivotal retinal disease trial

Outlook Therapeutics (NASDAQ:OTLK) completed patient enrollment in its pivotal clinical trial evaluating LYTENAVA, an ophthalmic formulation of bevacizumab, for use in retinal indications. Formerly known as ONS-5010...

July 7, 2020

Feature

Passage Bio developing transformative therapies for rare, life-threatening genetic disorders

Passage Bio (NASDAQ:PASG) is focused on developing transformative, differentiated therapies for rare, life-threatening monogenic CNS disorders, with the goal of mitigating development risk. “We believe that our rigorous...

June 30, 2020

Developments

Hepion advances to final dosing level in ongoing Phase 1 study of CRV431

Hepion Pharmaceuticals (NASDAQ:HEPA) advanced to the final dose level of CRV431 in its ongoing Phase 1 multiple ascending dose trial. The clinical trial management team determined the 300 mg dosing level to be safe and...

June 29, 2020

Developments

Iterum Therapeutics reports mixed topline results from Phase 3 sulopenem trial

Iterum Therapeutics (NASDAQ:ITRM) reported mixed topline results from its clinical trial assessing sulopenem, an anti-infective compound, in combination with probenecid for the treatment of uncomplicated urinary tract...

June 29, 2020

Developments

Kiniksa Pharma reports positive Phase 3 rilonacept data in pericarditis

Kiniksa Pharmaceuticals’ (NASDAQ:KNSA) rilonacept met its primary and major secondary efficacy endpoints in a Phase 3 recurrent pericarditis trial. The trial met its primary endpoint of time to pericarditis recurrence...

June 29, 2020

Developments

Orthofix FIREBIRD SI fusion system gets FDA clearance for low back pain

Orthofix Medical (NASDAQ:OFIX) received FDA clearance for its FIREBIRD SI fusion system and has treated its first patients for low back pain. The system is designed to compress and stabilize the sacroiliac (SI) joint...

June 29, 2020

Developments

Chiasma MYCAPSSA gets FDA approval for acromegaly

The FDA approved Chiasma’s (NASDAQ:CHMA) MYCAPSSA for the treatment of acromegaly, a rare, chronic disease characterized by the overproduction of growth hormone and insulin-like growth factor-1 hormone. MYCAPSSA...

June 26, 2020

Developments

iBio to be added to Russell 2000 and Russell 3000 indexes

iBio (NYSE AMERICAN:IBIO) will be added to the Russell 2000 and Russell 3000 indexes after markets open on June 29, as part of the Russell indexes annual reconstitution. In early trading on June 26, shares of iBio...

June 26, 2020

Author - Abby Hardy

Ziopharm doses first patient in Phase 1/2 pediatric brain tumor trial

Strongbridge Biopharma names John Johnson as CEO

Outlook Therapeutics completes enrollment in pivotal retinal disease trial

Passage Bio developing transformative therapies for rare, life-threatening genetic disorders

Hepion advances to final dosing level in ongoing Phase 1 study of CRV431

Iterum Therapeutics reports mixed topline results from Phase 3 sulopenem trial

Kiniksa Pharma reports positive Phase 3 rilonacept data in pericarditis

Orthofix FIREBIRD SI fusion system gets FDA clearance for low back pain

Chiasma MYCAPSSA gets FDA approval for acromegaly

iBio to be added to Russell 2000 and Russell 3000 indexes

General

More